Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,506.00
(
0.28%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
91.36
(
0.00%
)
Bitcoin
73,443.04
(
0.10%
)
News Focus
News Focus
Post# of 518941
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

georgejjl

Send PM Follow Ignore
Followers 149
Posts 26290
Boards Moderated 0
Alias Born 04/08/2004

georgejjl

Re: Pazzo1212 post# 468634

Friday, 08/30/2024 3:59:48 PM

Friday, August 30, 2024 3:59:48 PM

Post# of 518941
Pazzo1212, Thank you for posting the CTAD agenda.

Pre-specified SIGMAR1 Gene Variant Analysis in Phase IIb/III Trial Supports Precision Medicine Mechanism of Action (MoA) with Improved Treatment Effect of Blarcamesine in Early Alzheimer Disease
Marwan N. Sabbagh 1, Juan Carlos Lopez-Talavera 2, Kun Jin 2, William Robert Chezem 2, Christopher U. Missling 2
1Barrow Neurological Institute - Phoenix (United States), 2Anavex Life Sciences - New York (United States)

Good luck and GOD bless,
Bullish
Bullish
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News